Oct 16,2023

ArteraAI Validates its Prognostic Model in Advanced Prostate Cancer

ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announces new data that will be presented at the European Society for Medical Oncology’s (ESMO) Congress Oct. 20-24. These data demonstrate successful validation of ArteraAI’s prognostic model in advanced prostate cancer with stronger prognostic associations than individual clinical variables. Moreover, the model was also able to identify pathologic features from the biopsy slide images that were strongly associated with poor prognosis in prostate biopsies from high-risk localized (M0) and metastatic (M1) prostate cancer. The validation was conducted using final data from a number of STAMPEDE trials (NCT00268476). In this study, an MMAI prognostic model that was developed using digitized whole scan images from new prostate biopsies along with other clinical data such as Gleason scores, tumor stage, and PSA levels was used to determine long-term, clinically relevant outcomes, as defined in STAMPEDE

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 17,2023

Servier partners with Owkin with the aim of discovering and developing AI-driven precision therapeutics

Servier, a global independent pharmaceutical group, and Owkin, a French American biotech focused on applying artificial intelligence (AI) to drug discovery, development, and diagnostics, today announced an innovative partnership to use AI to advance and accelerate better-targeted therapies across multiple disease areas, including oncology. The two companies will initially tackle two major challenges within translational medicine and digital pathology. Owkin will apply state-of-the-art machine learning to Servier’s extensive clinical data in order to deliver novel insights into the underlying biology of disease, identifying the patient populations most likely to benefit from Servier’s new therapies to improve patient outcomes. The first project aims to identify tumor types, tumor microenvironments, as well as de-identified patient subgroups that may optimally respond to a Servier asset. The second project will explore the implementation of digital pathology and its potential to speed up screening and enable broader analysis of tissue-based biomarkers.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 23,2023 TOP STORY

Michigan Medicine harnesses the power of Sectra's digital pathology solution to enhance patient care and foster collaboration among physicians

International medical imaging IT and cybersecurity company Sectra announces that the US health and academic center Michigan Medicine is expanding its usage of Sectra's enterprise imaging solution by including Sectra's module for digital pathology. This will enable their pathologists to review and collaborate around cases, ultimately improving cancer diagnostics in the region. The pathologists will complement their use of microscopes with the digital solution, allowing them to review and collaborate around cases in a way that has not been possible before. They will now have instant and, if needed, remote access to digital images of tissue samples instead of relying on physical glass slides reviewed in microscopes.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 19,2023

Massive Bio and ONCOassist® Announce Strategic Partnership at ESMO 2023

In a significant development poised to reshape the oncology landscape, Massive Bio and ONCOassist have announced a strategic partnership at the European Society for Medical Oncology (ESMO) 2023 conference in Madrid. This collaboration aims to optimize patient-centric care and enhance physician engagement in clinical trials and cancer research. ONCOassist provides a suite of decision support tools designed for oncology healthcare professionals. The ONCOassist app is a central part of this suite, offering access to relevant and up-to-date tools and content for oncology professionals. Selin Kurnaz, CEO and Co-Founder of Massive Bio, commented, “At Massive Bio, our focus has been on harnessing AI and concierge services to provide real-time clinical trial options for patients and their oncologists. Collaborating with ONCOassist® enhances our capability to accelerate R&D and streamline trial enrollment processes.”

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 20,2023

Tempus Announces Five Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2023

Tempus, a leader in artificial intelligence and precision medicine, today announced five abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2023, which convenes in Madrid, Spain, from October 20-24, 2023.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 19,2023

Mayo Clinic and Oxford Nanopore announce collaboration to advance precision medicine for cancer and genetic disorders

Mayo Clinic and Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, today unveiled a multi-year joint development collaboration to develop new clinical tests for diseases and improve patient care. Nanopore sequencing is well positioned to serve Mayo Clinic’s goals of improving testing in some of the hardest-to-characterize conditions. The ability to sequence any-length fragments of DNA — from short to long and ultra-long — and examine methylation in real time offers the potential to provide clinicians with a more complete picture of an evolving cancer genome quickly and accurately. 

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Aug 16,2022

Aussie cancer start-up scores deal with $9b telehealth giant

CancerAid, an Aussie start-up that created a virtual coach to help cancer patients navigate their diagnosis and treatment journey has formed a joint venture with $US6.5 billion ($8.6 billion) telehealth giant Teladoc Health. CancerAid sells its services to 45 enterprises including Aon, Lendlease and MinterEllison, who then give staff going through cancer, or who are caring for someone with the disease, access to the program. It is joining forces with Teladoc in Australia and New Zealand to create a new product named Cancer Companion, which is specific for insurers. Revenue from Cancer Companion will be split evenly, and the companies have already signed up New Zealand-based insurer Fidelity Life.

COLLABORATION PARTNERSHIP

#r&d

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 17,2023 TOP STORY

Immersive Virtual Reality Seems to Ease Cancer Patients' Pain and Distress

Immersive virtual reality - digital technology that allows a person to experience being physically present in a non-physical world - seems to ease the pain and distress felt by patients with cancer, suggests a pooled data analysis of the available evidence published in BMJ Supportive & Palliative Care. The researchers trawled research databases for studies that looked at the use and effectiveness of immersive virtual reality for aiding psychological adjustment to a long term condition in adults. They found 31 relevant studies, published between 1993 and 2023, in which the technology had been used in patients with cancer (16), dementia (5), cardiovascular disease (4), MS (2), kidney disease (2), inflammatory bowel disease (1), and chronic obstructive pulmonary disease (1). Pooling the study results showed that patients were happy to use immersive virtual reality and that it helped those with cancer, dementia, cardiovascular disease, MS and kidney disease cope better with required medical treatments and the emotional impact of their condition. The types of virtual reality and procedures used varied widely across the included studies, and no one particular type emerged as noticeably more effective than any of the others.

CLINICAL STUDY

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Oct 16,2023

Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that nine oral presentations from the Company’s solid tumor portfolio and pipeline, with three highlighted in Presidential Symposium sessions, will be featured at the European Society for Medical Oncology (ESMO) 2023 Congress. In total, 19 studies (17 company-sponsored abstracts and two investigator-initiated studies), including seven late-breaking abstracts, will feature new data and updates in lung cancer, bladder cancer, and prostate cancer, highlighting Janssen’s pioneering efforts to transform the treatment of solid tumors.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 16,2023

Research featuring Elekta Kaiku, powered by Kaiku Health, to be presented at ESMO 2023

Elekta Kaiku, fka Kaiku Health, announced that the company is going to be a part of clinical research published at ESMO 2023 in the following sessions: “Patient adherence to digital patient-reported outcome monitoring (PROM) in cancer immunotherapies”; and “Enabling Patient Empowerment Through Digital Symptom Monitoring”.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY